688363 华熙生物
2024/09 - 九个月
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
2020/12
人民币(K¥)
经营活动产生之现金流量净额274,056699,648635,1891,276,060705,121
投资活动产生之现金流量净额(306,092)(612,882)(836,222)(989,864)(1,331,308)
筹资活动产生之现金流量净额(349,701)(527,566)(170,157)(71,356)(159,937)
汇率变动对现金及现金等价物的影响3,48210,56529,556(19,851)(12,354)
现金及现金等价物净增加/(减少)(378,254)(430,235)(341,634)194,988(798,479)
期初现金及现金等价物余额813,0601,243,2951,584,9301,389,9422,188,420
期末现金及现金等价物余额434,806813,0601,243,2951,584,9301,389,942